Dose-Dense Therapy in Aggressive Lymphoma

• Status: No longer available
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To investigate if a dose-dense chemotherapy with weekly chemotherapy compared to standard treatment every 3 weeks results in better survival in aggressive non-Hodgkin's lymphoma.

Details

• Lead Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie

Criteria

Inclusion Criteria:

• 18 and 70 years of age

• Centrally reviewed, histologically proven diffuse large B-cell, anaplastic large-cell, or peripheral T-cell unspecified

• Measurable disease

• All stages

Exclusion Criteria:

• Lymphoblastic or Burkitt histology

• CNS-disease

• HIV-positive

• pregnant or lactating women

• Pretreatment

• Other malignancy

• Concomitant diseases that forbid chemotherapy